However, in clinical practice, the impact of mTOR inhibitors in preventing HCC recurrence after LT is still controversial, with a potential benefit described in observational retrospective studies [13,14,15], which could not be confirmed in prospective studies and randomized trials [16,17]. This evidence concerns the gene MTOR and hepatocellular carcinoma.